Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Receivables for 10 consecutive years, with $181.5 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 3.32% to $181.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $181.5 million through Dec 2025, down 3.32% year-over-year, with the annual reading at $181.5 million for FY2025, 3.32% down from the prior year.
  • Receivables hit $181.5 million in Q4 2025 for Ascendis Pharma A, down from $187.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $187.7 million in Q4 2024 to a low of $25.2 million in Q4 2022.
  • Historically, Receivables has averaged $95.8 million across 5 years, with a median of $59.1 million in 2023.
  • Biggest five-year swings in Receivables: surged 217.38% in 2024 and later dropped 3.32% in 2025.
  • Year by year, Receivables stood at $25.5 million in 2021, then dropped by 1.01% to $25.2 million in 2022, then soared by 134.3% to $59.1 million in 2023, then soared by 217.38% to $187.7 million in 2024, then decreased by 3.32% to $181.5 million in 2025.
  • Business Quant data shows Receivables for ASND at $181.5 million in Q4 2025, $187.7 million in Q4 2024, and $59.1 million in Q4 2023.